EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nabriva Therapeutics's Enterprise Value is $-1.64 Mil.
Nabriva Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 was $-13.02 Mil. Therefore, Nabriva Therapeutics's EV-to-FCF for today is 0.13.
The historical rank and industry rank for Nabriva Therapeutics's EV-to-FCF or its related term are showing as below:
NBRVF'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.69 Med: -0.15 Max: 0.3
Current: 0.13
During the past 10 years, the highest EV-to-FCF of Nabriva Therapeutics was 0.30. The lowest was -1.69. And the median was -0.15.
NBRVF's EV-to-FCF is ranked better than 90.56% of 392
companies
in the Biotechnology industry
Industry Median: 4.3
vs NBRVF: 0.13
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The historical data trend for Nabriva Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nabriva Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Nabriva Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nabriva Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Nabriva Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nabriva Therapeutics's EV-to-FCF falls into.
Nabriva Therapeutics's current Enterprise Value is $-1.64 Mil.
Nabriva Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.02 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Nabriva Therapeutics's PE Ratio for today is calculated as:
Nabriva Therapeutics's share price for today is $0.0001.
Nabriva Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-18.430.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nabriva Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Nabriva Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Nabriva Therapeutics (Nabriva Therapeutics) Business Description
Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company has developed a product candidate, XENLETA, a semi-synthetic pleuromutilin antibiotic that is the first in its class for oral and IV administration in humans. XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. The firm has commercial rights to two approved products, SIVEXTRO and XENLETA, as well as one development product candidate, CONTEPO.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NBRVF has been successfully added to your 